Daily Endocrinology Research Analysis
Three impactful endocrinology papers advance cardiometabolic care. A nationwide emulated trial shows GLP-1 receptor agonists and SGLT2 inhibitors reduce major cardiovascular events across moderate baseline risk in type 2 diabetes. A large population-based cohort links gestational glucose intolerance and screening gaps to markedly higher 5-year postpartum diabetes risk, while a randomized pilot demonstrates that slower, flexible semaglutide titration cuts gastrointestinal adverse events without s
Summary
Three impactful endocrinology papers advance cardiometabolic care. A nationwide emulated trial shows GLP-1 receptor agonists and SGLT2 inhibitors reduce major cardiovascular events across moderate baseline risk in type 2 diabetes. A large population-based cohort links gestational glucose intolerance and screening gaps to markedly higher 5-year postpartum diabetes risk, while a randomized pilot demonstrates that slower, flexible semaglutide titration cuts gastrointestinal adverse events without sacrificing glycemic efficacy.
Research Themes
- Cardiometabolic therapeutics effectiveness across risk strata
- Pregnancy-related dysglycemia and postpartum diabetes risk
- Tolerability-driven optimization of GLP-1 therapy
Selected Articles
1. Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.
In a nationwide emulated comparative effectiveness study of 386,276 adults with type 2 diabetes and moderate cardiovascular risk, GLP-1 receptor agonists and SGLT2 inhibitors conferred lower major adverse cardiovascular events than sulfonylureas or DPP-4 inhibitors. Absolute risk reductions were larger in patients with higher baseline risk, but benefits were present across all risk strata.
Impact: This large-scale real-world analysis extends cardiovascular benefits of GLP-1RAs and SGLT2is to patients with moderate risk, informing second-line therapy choices beyond high-risk populations.
Clinical Implications: Prefer GLP-1RAs or SGLT2 inhibitors over sulfonylureas/DPP-4 inhibitors as second-line therapy in type 2 diabetes irrespective of moderate baseline cardiovascular risk, recognizing larger absolute benefits in higher-risk individuals.
Key Findings
- By year 3, absolute MACE reduction was larger in higher-risk vs lower-risk patients for GLP-1RA vs sulfonylurea (3.1% vs 1.6%) and SGLT2i vs sulfonylurea (3.9% vs 1.3%).
- GLP-1RA vs DPP-4i yielded absolute MACE reduction of 1.6% (higher-risk) and 0.5% (lower-risk).
- Relative benefit of SGLT2i vs DPP-4i was greater in higher-risk (HR 0.78, 95% CI 0.70–0.87) than lower-risk (HR 0.99, 95% CI 0.88–1.12) patients.
- Benefits of SGLT2is and GLP-1RAs were observed across the entire moderate-risk spectrum.
Methodological Strengths
- Very large nationwide cohort with trial emulation framework
- Risk stratification using a validated claims-based MACE estimator
Limitations
- Observational design with potential residual confounding and confounding by indication
- Claims data may misclassify exposures/outcomes and cannot fully capture adherence or clinical detail
Future Directions: Prospective pragmatic trials in moderate-risk populations and head-to-head comparisons focusing on absolute risk reduction, cost-effectiveness, and patient-centered outcomes.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have favorable cardiovascular outcomes compared with dipeptidyl peptidase-4 inhibitors (DPP4is) and sulfonylureas in adults with type 2 diabetes and high cardiovascular risk. How these benefits vary across lower levels of cardiovascular risk is unknown. METHODS: We used nationwide claims data to emulate a comparative effectiveness trial and examine the heterogeneity of treatment effects of GLP-1RAs, SGLT2is, DPP4is, and sulfonylureas on major adverse cardiovascular events (MACEs) among adults with type 2 diabetes and moderate cardiovascular risk (annualized MACE risk 1%-5%, estimated using the annualized claims-based MACE estimator). RESULTS: Among 386 276 included adults with type 2 diabetes, 25.2% had baseline ACME-predicted MACE risk >1% to ≤2% (lower-risk patients) and 13.3% had ACME-predicted risk >4% to ≤5% (higher-risk patients). By year 3 of treatment, higher-risk patients derived greater absolute benefit than lower-risk patients when treated with GLP-1RAs versus sulfonylureas (absolute reduction in the estimated rate of MACE of 3.1% in higher-risk patients and 1.6% in lower-risk patients), SGLT2is versus sulfonylureas (absolute reduction, 3.9% in higher-risk patients and 1.3% in lower-risk patients), and GLP-1RAs versus DPP4is (absolute reduction, 1.6% in higher-risk patients and 0.5% in lower-risk patients). The relative benefits for MACE were also greater in higher-risk than lower-risk patients with SGLT2is versus DPP4is (hazard ratio [HR], 0.78 [95% CI, 0.70-0.87] in higher-risk patients; HR, 0.99 [95% CI, 0.88-1.12] in lower-risk patients). Conversely, the relative benefits of DPP4is and GLP-1RAs versus sulfonylureas were greater in lower-risk patients: HR 0.76 (95% CI, 0.71-0.81) in lower-risk and HR 0.91 (95% CI, 0.97-0.96) in higher-risk patients for DPP4is versus sulfonylureas; HR 0.67 (95% CI, 0.58-0.78) in lower-risk and HR 0.80 (95% CI, 0.70-0.93) in higher-risk patients for GLP-1RAs versus sulfonylurea. Benefits of SGLT2is and GLP-1RAs were comparable across all risk levels. CONCLUSIONS: Cardiovascular benefits of SGLT2is and GLP-1RAs exist across all levels of moderate cardiovascular risk, reinforcing the importance of choosing glucose-lowering therapies that can prevent MACE in all people with type 2 diabetes.
2. Gestational Diabetes-Screening, Prevalence and Postpartum Diabetes: Population-Based Cohort Study.
In a population-based cohort of 128,454 births across three Israeli HMOs, GDM prevalence was 4.3% and 10% of women were unscreened. Five-year postpartum diabetes risk was markedly higher with GDM (adjusted OR 25.48), unknown GDM status (OR 10.04), impaired glucose tolerance on OGTT (OR 6.48), and even abnormal OGCT with normal OGTT (OR 2.17), highlighting screening gaps and sociodemographic disparities.
Impact: This large, registry-linked cohort quantifies postpartum diabetes risk across the spectrum of gestational dysglycemia and identifies gaps in screening, offering concrete targets for intervention and health equity.
Clinical Implications: Improve GDM screening coverage and follow-up; prioritize postpartum diabetes surveillance for women with any gestational dysglycemia (including single abnormal OGTT value or abnormal OGCT) and address sociodemographic disparities.
Key Findings
- GDM prevalence was 4.3%; 10% of women were unscreened for GDM.
- Five-year postpartum diabetes adjusted ORs: GDM 25.48; unknown GDM status 10.04; impaired glucose tolerance (one abnormal OGTT value) 6.48; abnormal OGCT with normal OGTT 2.17.
- Older age, lower socioeconomic status, and Arab/Bedouin ethnicity were associated with higher GDM and postpartum diabetes risk.
Methodological Strengths
- Population-based design covering 75% of births with registry linkage
- Standardized two-step screening protocol and multivariable adjustment
Limitations
- Retrospective analysis with potential misclassification and incomplete screening data
- Findings from Israeli HMOs may have limited generalizability
Future Directions: Evaluate strategies to close screening gaps and test postpartum diabetes prevention programs tailored by risk and sociodemographic profile.
AIMS: To evaluate GDM screening compliance and prevalence, and the association between gestational glucose intolerance and 5-year postpartum diabetes mellitus (DM). MATERIALS AND METHODS: We used population-based data from three Israeli health maintenance organisations (HMOs), covering 75% of all births in 2016. GDM screening followed a two-step approach: a 50-g 1-h oral glucose challenge test (OGCT), followed by a 100-g 3-h oral glucose tolerance test (OGTT) using Carpenter-Coustan criteria. Data included age, socioeconomic status (SES), results of OGCT and OGTT tests, child birth weight, and gestational age. The dataset was linked to the Israeli National Diabetes Registry to identify postpartum DM. Logistic regression models estimated odds ratios (ORs) for GDM and postpartum DM, adjusting for maternal age, SES, ethnicity, and glucose tolerance status. RESULTS: Among 128,454 women, 10% were unscreened. Of those screened, 23,451 underwent the full OGTT. GDM prevalence was 4.3%. Postpartum DM incidence was 8.6% in women with GDM, 3.1% with unknown GDM status, and 2.1% with impaired glucose tolerance (IGT) (defined as one abnormal value on the OGTT). Compared with normoglycemia, adjusted ORs for the 5-year postpartum DM were 25.48 (95% CI: 21.80-29.79) for GDM, 10.04 (95% CI: 8.59-11.74) for unknown GDM status, 6.48 (95% CI: 5.07-8.28) for IGT, and 2.17 (95% CI: 1.63-2.88) for abnormal OGCT with normal OGTT. Older age, lower SES, and Arab or Bedouin ethnicity were linked to higher GDM and postpartum DM. CONCLUSIONS: Gestational glucose intolerance and screening gaps were strong predictors of postpartum DM. Age, SES, and ethnicity highlight the need for targeted efforts to reduce health disparities.
3. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
In a randomized open-label pilot (n=104), a 16-week flexible semaglutide titration (weekly micro-steps with GI-AE-based delays) reduced GI-related withdrawals (2% vs 19%), nausea frequency/days, and asthenia compared with the 8-week label regimen, with similar HbA1c and BMI reductions at 26 weeks.
Impact: Tolerability is a major barrier to GLP-1RA persistence. This pragmatic titration strategy demonstrates a simple, scalable approach to improve adherence without compromising efficacy.
Clinical Implications: Consider slower, flexible semaglutide titration with small weekly increments and temporary delays for GI symptoms to reduce discontinuation and improve patient adherence.
Key Findings
- GI-AE–related discontinuation was significantly lower with flexible titration (2%) versus label-recommended titration (19%; P=0.005).
- Flexible titration reduced nausea prevalence (45.1% vs 64.2%; P=0.051), days with nausea (2.88 vs 6.3; P=0.017), and asthenia (9.8% vs 24.5%; P=0.047).
- HbA1c and BMI improvements were similar between groups over 26 weeks.
Methodological Strengths
- Randomized controlled design directly comparing titration strategies
- Patient-centered flexible protocol responsive to GI adverse events
Limitations
- Open-label pilot with small sample size and limited duration
- Not powered for efficacy differences; generalizability requires confirmation
Future Directions: Confirm in larger, blinded, multicenter trials across doses and indications (including obesity), and assess long-term persistence, patient-reported outcomes, and cost-effectiveness.
OBJECTIVE: To determine whether a slower, flexible titration regimen of semaglutide would improve adherence and reduce gastrointestinal adverse events (GI-AEs) compared with the label-recommended regimen in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 104 patients with T2D were randomized to label-recommended titration (0.25 mg, 0.5 mg, 1 mg at 4-week intervals) or flexible titration (starting at 0.0675 mg [measured as five clicks made by the dose selector dial], with gradual increases by 0.0675 mg/week and delays for GI-AEs) for 26 weeks. RESULTS: While final doses were similar between groups, only 2% of patients in the flexible arm withdrew due to GI-AEs vs. 19% in the label arm (P = 0.005). The flexible arm reported less nausea (45.1% vs. 64.2%; P = 0.051) and asthenia (9.8% vs. 24.5%; P = 0.047), with fewer days experiencing nausea (2.88 vs. 6.3 days; P = 0.017). HbA1c and BMI changes were similar between groups. CONCLUSIONS: Slower, flexible titration improved adherence and reduced adverse events without compromising efficacy.